Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1,873

Chronic inflammation causes a reduction in NAD+

NAD+ (nicotinamide adenine dinucleotide), a key metabolite central to an efficient and healthy metabolism, declines with age. This previously unexplained phenomena is associated with numerous age-related diseases and has spawned the development of many nutritional supplements aimed at restoring NAD+ to more youthful levels. Publishing in Nature Metabolism, researchers at the Buck Institute have identified chronic inflammation as a driver of NAD+ decline. They show that an increasing burden of senescent cells, which is also implicated in the aging process, causes the degradation of NAD via the activation of CD38 (cyclic ADP ribose hydrolase) a protein that is found on the cell membranes both inside and on the surface of many immune cells.

“We are very excited to link two phenomena which have been separately associated with aging and age-related disease,” said Eric Verdin, MD, Buck Institute President and CEO and senior author of the paper. “The fact that NAD+ decline and are intertwined provides a more holistic, systemic approach to aging and the discovery of CD38 macrophages as the mediator of the link between the two gives us a new target for therapeutic interventions.”

Separate Antiaging Trials for Rapamycin and Metformin


AgelessRx claims that PEARL is the first nationwide telemedicine trial and one of the first large-scale intervention trials on Longevity. The human trial is a stepping stone to the way to bringing rapamycin to the Longevity market. PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) is a $600,000 trial with the University of California. They will evaluate the safety and effectiveness of rapamycin in 200 healthy adults for Longevity in double-blind, randomized, placebo-controlled trial.

Interested patients will be screened for eligibility using telemedicine. Eligible patients include those aged 50–85 of any sex, any ethnicity, in relatively good health, with only well-managed, clinically stable chronic diseases.

TAME is a separate $75 million trial to clinically evaluate Metformin drugs for Longevity properties. TAME has a composite primary endpoint – of stroke, heart failure, dementia, myocardial infarction, cancer and death. Rather than attempting to cure one endpoint, it will look to delay the onset of any endpoint, extending the years in which subjects remain in good health – their healthspan. A $40 million donation has been combined with a $35 million NIH grant to fund the TAME trial.

Pearls may provide new information processing options for biomedical, military innovations

Pearls have long been favored as objects of beauty. Now, Purdue University innovators are using the gem to provide potential new opportunities for spectral information processing that can be applied to spectroscopy in biomedical and military applications.

The Purdue team demonstrated transport-assisted information processing by creating a .

Spectrometers probe interactions of matter and light as a function of the electromagnetic spectrum and are commonly used in biomedical and . For example, they have been used for diagnostics of various types of cancer and for military gas sensing.

Scientists develop next-generation immunotherapy now entering early phase clinical trials

Cancer Research UK scientists have invented a new experimental drug that aims to harness the full power of the body’s own immune system, launching a two-pronged response against cancer, according to a study published in Nature Cancer today.

In the study, partly funded by Cancer Research UK, the new immunotherapy , which targets suppressive ‘regulatory’ immune cells inside a tumor, significantly improved long-term survival in animal models even when used without other drugs.

If this, and larger follow-up trials, are successful, it could lead to a new immunotherapy treatment for people with high numbers of a certain type of immune cell that are found in cancers including melanoma, some lung cancers and head and neck .The drug is now being developed in early phase clinical trials to determine its safety in people with advanced cancer.

Chinese firm turns panda poop into toilet paper

Circa 2017 o.o

When life gave one Chinese company giant panda poop, it decided to make paper — and profits. The Qianwei Fengsheng Paper Company in southwest Sichuan province has teamed up with the China Conservation and Research Center for the Giant Panda to recycle the animal’s faeces and food debris into toilet paper, napkins and other household products, state media reported Wednesday. The goods, soon to be released on the Chinese market, will be marketed as part of a “panda poo” product line decorated with a picture of the bamboo-eating, black-and-white bear. “They’re taking care of our garbage for us,” Huang Yan, a researcher at the giant panda centre, told the Chengdu Business Daily. Huang told Xinhua state news agency that the 10 kilograms (22 pounds) of bamboo poo that adult pandas unleash daily are rich in fibre after absorbing the fructose from the shoots. In addition to their valuable dung, pandas also produce 50 kilograms of food waste every day from the bamboo husks they spit out after chewing. While the process of turning bamboo into paper generally involves the breaking down of fructose to extract fibre, this step naturally occurs in the pandas’ digestive tract, the paper company’s president, Yang Chaolin, told Xinhua. Fengsheng will collect the faeces from three panda bases in Sichuan a couple of times a week. After it is boiled, pasteurised and turned into paper, it will be tested for bacteria before going on sale. Boxes of “panda poo” tissues will be sold at 43 yuan ($6.5) a pop. “Pandas get what they want and we do too,” Yang said. “It’s a win-win.”

‘He came back from the dead’: Lost Mount Rainier hiker starts to recover after rescue in whiteout conditions

It took dozens of park rangers, searchers, doctors and nurses, but Michael Knapinski, who became lost amid freezing, whiteout conditions in Mount Rainier National Park last weekend, was brought back to life in what his medical team is calling a miraculous recovery.

The 45-year-old from Woodinville was on a snowy hike with a friend on the morning of Nov. 7. The two separated below the Muir Snowfield. His friend planned to continue on skis to Camp Muir while Knapinski snowshoed down toward Paradise, where they expected to meet up.

“I was pretty close to the end (of the trail). … Then it turned to whiteout conditions, and I couldn’t see anything,” Knapinski told The Seattle Times in a phone interview Friday. The last thing he said he remembers is taking baby steps down the mountain, surrounded by white.

Can We Change Our Genes & DNA With Our Thoughts?

A 2002 article published in the American Psychological Association’s prevention & treatment, by University of Connecticut psychology professor Irving Kirsch titled, “The Emperor’s New Drugs,” made some more shocking discoveries. He found that 80 percent of the effect of antidepressants, as measured in clinical trials, could be attributed to the placebo effect. This professor even had to file a Freedom of Information Act (FOIA) request to get information on the clinical trials of the top antidepressants.

A Baylor School of Medicine study, published in 2002 in the New England Journal of Medicine, looked at surgery for patients with severe and debilitating knee pain. Many surgeons know there is no placebo effect in surgery, or so most of them believe. The patients were divided into three groups. The surgeons shaved the damaged cartilage in the knee of one group. For the second group, they flushed out the knee joint, removing all of the material believed to be causing inflammation. Both of these processes are the standard surgeries people go through who have severe arthritic knees. The third group received a “fake” surgery, the patients were only sedated and tricked that they actually had the knee surgery. For the patients not really receiving the surgery, the doctors made the incisions and splashed salt water on the knee as they would in normal surgery. They then sewed up the incisions like the real thing and the process was complete.

Scientists Seek To Inject Microscopic Robots Into Patients To Hunt Disease

Would you be okay to have these injected in you?

Engineers at Cornell University developed a microscopic robot – so small it’s invisible to the naked eye – that walks. It’s so tiny that ten could fit within a period. The team says they can manufacture one million of the robots per week.

The new robot is essentially a microchip on four origami-inspired legs that can be activated by lasers. It was designed to crawl inside the human body, find and eliminate diseases. It can be steered by beaming a laser at its feet, which causes their leg to bend.

Itai Cohen and Paul McEuen Labs, leaders of this invention, envisions them as a beneficial medical tool to do things like hunt down and destroy cancer cells. The micro-bots are so small they can be injected into the body.

Biologist Rob Lue, founding HarvardX faculty director, dies at 56

Sean Eddy stood awkwardly next to fossil exhibits at a 2015 wine reception at the Harvard Museum of Natural History. He was new to the University and didn’t know a soul. Then up strolled a smiling Rob Lue, who “started telling me about his new work on data-driven urban planning in Paris, and we immediately hit it off,” Eddy recalls.

The Ellmore C. Patterson Professor of Molecular and Cellular Biology and department chair would eventually come to learn that Lue was a highly regarded researcher, an energetic leader in innovative teaching, and roundly cherished for his warm and generous spirit. “Rob was an optimist with a passion that would draw you in and get you talking with him about the good things in the world — art and books and education — and how we could make the world an even better place together,” Eddy said. “He saw the best in people.”

Lue, who died Wednesday at 56 from cancer, had an impact felt deeply among undergraduates on campus and beyond. He was professor of the practice in the Department of Molecular and Cellular Biology, founding faculty director of HarvardX, faculty director of the Harvard Ed Portal, Richard L. Menschel Faculty Director of the Derek Bok Center for Teaching and Learning, UNESCO Chair on Life Sciences and Social Innovation, and faculty director and principal investigator of LabXchange.